Our findings suggest that ICI‐based therapy might serve as a treatment option for advanced NSCLC patients with HER2 mutations, and that those harbouring HER2 non‐ex20ins mutations could potentially benefit more. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.